MCK: Hold with a $883.91 price target

Borrowing is lower relative to earnings, but year-to-date profit is lower.

Target for 2027-09-11: $883.91 USD, +0.3% versus the $881.51 weekly close on 2026-09-11. Price return only; dividends, fees and tax excluded.

Over 1 year (2025-09-12 to 2026-09-11), price changed +23.9% and trailing EPS changed +21.9%. A wider gap changes the earnings multiple; it does not establish fair value.

Net debt / EBITDA: 0.9× for MCK, against 1.4× across 6 comparable peers.

Over one year, the stock changed +23.9% against +19.7% for Healthcare (XLV). The gap is +4.2 percentage points. These are price returns, before dividends.

Across 1 completed quarters since 2026-03-31, net income was 614.0m versus 784.0m in the matching prior-year periods (USD). Check whether the latest quarter changes that direction.

Net income was 614.0m, compared with 784.0m in the same quarter last year. Amounts are in USD.

The latest quarterly margin changed +0.2 percentage points from a year earlier. Check sales volumes, pricing and unusual gains in the next filing.

Recheck the valuation gap alongside profitability and growth after new results. A discount alone does not establish value.

Compare the stock and the market fund over the same dates. Look for a change in relative performance as results arrive.

Starting annual sales growth: 8.93%.

Net profit margin: 1.04%.

Review recorded on 2026-09-17. This is a dated summary of an automated company valuation. The full report includes the financial evidence, alternative scenarios and review history. Consult the latest report before using an earlier target. Automated model research, not personal investment advice. Targets depend on assumptions; returns are not guaranteed.